CG
CYTK icon

Cynosure Group’s Cytokinetics CYTK Stock Holding History

Cynosure Group’s Portfolio CYTK Stock Details CYTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-7,354
Closed -$467K – 273
2025
Q4 		$467K Sell
7,354
-3,018
-29% -$188K 0.05% 236
2025
Q3 		$570K Hold
10,372
– – 0.06% 144
2025
Q2 		$343K Buy
10,372
+2,584
+33% +$89.9K 0.04% 349
2025
Q1 		$313K Buy
7,788
+1,988
+34% +$91.4K 0.04% 338
2024
Q4 		$273K Sell
5,800
-1,071
-16% -$55.6K 0.04% 349
2024
Q3 		$363K Buy
+6,871
New +$383K 0.05% 315

Other funds holding CYTK

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Cynosure Group's CYTK Position: Q1 2026 in Review

Cynosure Group sold out of Cytokinetics (CYTK) in Q1 2026, closing a stake of 7,354 shares — an estimated $467K sold.

Cynosure Group first reported a position in CYTK in Q3 2024 and held it in 6 quarters. The position peaked at $570K in Q3 2025. 439 funds tracked by Wall St. Rank hold CYTK as of Q1 2026.

  • Cynosure Group reported no remaining Cytokinetics position as of Q1 2026 after selling out during the quarter.
  • Cynosure Group sold 7,354 Cytokinetics shares in Q1 2026, an estimated $467K.
  • Cynosure Group first reported a position in Cytokinetics in Q3 2024 and held it in 6 quarters.
  • Cynosure Group's Cytokinetics position peaked at $570K in Q3 2025.
  • 439 funds tracked by Wall St. Rank held Cytokinetics as of Q1 2026.

Based on Cynosure Group's 13F filing for Q1 2026, filed 14 May 2026.